Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 23 October 2013 | By Alexander Gaffney, RAC,
US regulators are once again warning consumers that they are nearing the end of a multi-year process to phase out all medical products containing chlorofluorocarbons (CFCs), a propellant used in some asthma inhalers that is more broadly linked to the depletion of the ozone layer.
The removal of the inhalers from the market has long been planned under an environmental protocol signed by the US in 1987 known as the Montreal Protocol, an international agreement meant to preserve the ozone layer by phasing out the use of CFCs, which were then commonly used as propellants in aerosol canisters.
Despite the Protocol's phase-out plan, it took until 2006 for FDA and the Environmental Protection Agency (EPA) to develop rules to implement the CFC phase-out.
By 2008, both EPA and FDA's attempts to get all manufacturers to switch to different propellants had failed, with at least one-Amphastar, manufacturer of Primatene-underwriting a lobbying campaign against the proposed ban. Critics contended the amount of CFCs emitted by the products were insignificant and would be of no consequence to the ozone layer. Those arguments lost out, and on 1 January 2012, FDA finally acted to ban the products from the market.
In May 2013, FDA issued a warning to consumers that the last two inhalers on the market containing CFCs-Combivent Inhalation Aerosol and the Maxair Autohalar, both prescription products-will be unavailable as of 1 January 2014.
Now it's repeating a similar warning, reminding consumers that the end of CFC propellants is right around the corner, and to plan accordingly.
Regulators said disruptions should largely be minimized, as there "are many safe and effective inhalers available to treat asthma and COPD symptoms [that do not contain CFCs]," FDA wrote.
FDA notes that albuterol inhalers, the most common type used to treat asthma, were removed from the market in 2008 and replaced with a hydrofluoroalkanes (HFA)-based propellant. Combivent had an alternative approved in 2011 that contains the same active ingredients but does not contain the CFCs. Alternatives to Maxair include albuterol or levalbuterol, FDA said.
However, consumers will have to obtain a new prescription for the products, which will require them to assume the cost of seeing a healthcare professional. The last over-the-counter asthma inhaler, Primatene, was taken off the market in 2011 by FDA, angering some legislators who said the lack of access could harm patients. However, other asthma groups have made the opposite argument, saying that the condition of asthma requires the oversight of a medical practitioner to ensure safe and proper use.
FDA Announcement on CFCs
Tags: Inhaler, EPA
Regulatory Focus newsletters
All the biggest regulatory news and happenings.